Non-clear cell renal cell carcinoma, part 2: therapy

Non-clear cell renal cell carcinomas (RCCs) represent a heterogeneous group of diseases with distinct molecular drivers, histologies, and clinical outcomes. Their low incidence and heterogeneity have resulted in a lack of studies that address the optimal strategies for each subtype. This article (th...

Full description

Saved in:

Bibliographic Details
Published in:	Clinical advances in hematology & oncology Vol. 13; no. 6; pp. 383 - 391
Main Authors:	Valenca, Loana B, Hirsch, Michelle S, Choueiri, Toni K, Harshman, Lauren C
Format:	Journal Article
Language:	English
Published:	United States 01-06-2015
Subjects:	Antineoplastic Agents - therapeutic use Carcinoma, Renal Cell - drug therapy Carcinoma, Renal Cell - metabolism Humans Kidney Neoplasms - drug therapy Kidney Neoplasms - metabolism Molecular Targeted Therapy Neoplasm Proteins - antagonists & inhibitors
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Non-clear cell renal cell carcinomas (RCCs) represent a heterogeneous group of diseases with distinct molecular drivers, histologies, and clinical outcomes. Their low incidence and heterogeneity have resulted in a lack of studies that address the optimal strategies for each subtype. This article (the second in a 2-part series) reviews the current targeted therapies approved for RCC, such as the vascular endothelial growth factor receptor tyrosine kinase inhibitors and the mammalian target of rapamycin inhibitors. Ongoing studies will provide more information regarding the role of these agents in non-clear cell RCC. Ultimately, enhanced understanding of genetic triggers and the development of more tailored treatments remain imperative to improve outcomes in non-clear cell RCC.
Bibliography:	ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-3 content type line 23 ObjectType-Review-1
ISSN:	1543-0790